## SHW: Sherwin-Williams Company (The) - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%); PEG 3.31 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($316.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Get To Know the Global Color Experts Shaping Sherwin-Williamsâ€™ Next Big Hues**
- Source: Cleveland Magazine | 20251211T100441 | Bullish | Relevance: 98%
- Sherwin-Williams relies on its Trendsight Team, a global collective of experts, to forecast color trends and inform its annual Colormix Forecast. This team analyzes cultural shifts, economic signals, and emerging movements across various industries. For 2026, they have named Universal Khaki SW 6150 as the Color of the Year, chosen for its ability to convey comfort, warmth, and timeless style in homes.

**2. Assessing Sherwin-Williams (SHW) Valuation After Its Recent Share Price Pullback**
- Source: Simply Wall Street | 20251209T123859 | Somewhat-Bullish | Relevance: 98%
- Sherwin-Williams (SHW) shares have recently pulled back, showing an 8.5% decline over 90 days, despite continued earnings and revenue growth. While a narrative-driven valuation suggests the stock is 15.4% undervalued with a fair value of $386.52, current market ratios indicate it's expensive at 31.4 times earnings compared to industry averages. This discrepancy prompts investors to consider whether the stock is an undervalued opportunity or if its premium is unsustainable.

**3. With A 5.9% Return On Equity, Is H.B. Fuller Company (NYSE:FUL) A Quality Stock?**
- Source: Simply Wall Street | 20251210T111116 | Neutral | Relevance: 62%
-  This article analyzes H.B. Fuller Company (NYSE:FUL) using Return On Equity (ROE) as a key metric. It highlights H.B. Fuller's ROE of 5.9%, which is lower than the Chemicals industry average of 9.6%. The analysis also points out the company's high debt-to-equity ratio of 1.14, suggesting that H.B. Fuller relies significantly on debt to boost its returns, which is considered less appealing when combined with a low ROE.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 16 ($0.21M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.1% (+1.4%)
- Blackrock Inc.: 7.1% (-0.7%)
- State Street Corpora: 6.2% (-0.9%)
- Price (T.Rowe) Assoc: 3.6% (-1.7%)
- Morgan Stanley: 2.9% (+1.8%)

### Key Risks

1. Valuation stretched: PEG 3.3x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.31 signals overvaluation risk, limited margin of safety. Forward P/E 26.1x stretched relative to 11% growth. Quality metrics strong (ROE 60%). Balance sheet: $1.1B free cash flow. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $82.1B |
| Beta | 1.24 |
| 52W Range | $308.84 - $379.65 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.31 |
| Forward P/E | 26.1 |
| Current P/E | 28.9 |
| YoY Growth | 11.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.4% to -1.7% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Below SMA200 (0.95x), long-term trend not supportive. MACD histogram bearish (-1.14), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.66% (CS: 20) | Neutral |
| RSI_14 | 44.2 | Neutral |
| MACD Histogram | -1.14 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 0.951x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $329.30
- **Stop Loss:** $316.30 (3.9% risk)
- **Target:** $342.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 106
- **Position Value:** $34,905.80
- **Portfolio %:** 34.91%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-03 (Est: $2.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.44 | $3.59 | +4.4% |
| 2025Q2 | $3.81 | $3.38 | -11.2% |
| 2025Q1 | $2.16 | $2.25 | +4.1% |
| 2024Q4 | $2.06 | $2.09 | +1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*